Dr. Ayalew Tefferi, MD

Dr. Tefferi practices at Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota.

Dr. Tefferi's NPI, 1518946987, was assigned on January 12, 2006. Dr. Tefferi graduated from University of Athens in 1981. Dr. Tefferi's Minnesota license number on file is 30577.

Dr. Tefferi's primary practice is Mayo Clinic Breast Diagnostic Clinic, at 200 First Street SW, Rochester, MN 55905. The practice phone is (507) 284-5968.

Dr. Tefferi's primary practice is Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota. Dr. Tefferi is also affiliated with Mayo Clinic Hospital, Saint Marys Campus. The medical group on file is Mayo Clinic. Dmand AI also links Dr. Tefferi to 1 more clinical lab and 1 hospice, each named with a free account. Dr. Tefferi's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tefferi practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Tefferi's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Tefferi is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Tefferi's licenses on file in 2 states: Minnesota and Illinois.

Dmand AI lists chronic anemia and chronic leukemia among the conditions Dr. Tefferi treats.

CMS data shows 3,187 Medicare services from Dr. Tefferi across 10 procedure codes in 2024, for 152 Medicare patients. Medicare paid $56,460 for them. Every service was in an office.

CMS counts 152 Medicare patients who saw Dr. Tefferi in 2024. The largest group is 65 to 74, with 75 patients. 64% of them have high blood pressure, and 62% have high cholesterol. Their average risk score is 1.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tefferi's median patient age at 69, with 58% women.

In 2024, Dr. Tefferi wrote 208 Medicare Part D claims for 46 patients. 38% of them were for generic drugs. CMS names the drug for 183 of them, across 6 drugs with 11 or more claims each, at $2,734,909 in total drug cost. In 2023, CMS named 34 claims across 1 drug.

Dr. Tefferi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tefferi as offering telehealth.

Dmand AI links 913 papers to Dr. Tefferi, published from 2002 to 2025. 2023 was the busiest year, with 47. The most frequent topics are Primary Myelofibrosis, Janus Kinase 2 and Myeloproliferative Disorders. Dr. Tefferi has published most often in Am J Hematol. Dr. Tefferi's most frequent co-authors are Naseema Gangat, MBBS, Animesh D. Pardanani, MBBS, PhD and Mark R. Litzow, MD.

Dmand AI links Dr. Tefferi to 5 clinical trials, 3 of them phase 1/2 studies. Conditions studied include Primary Myelofibrosis, Myeloproliferative Disorders and Thrombocythemia, Essential. Sierra Oncology LLC - a GSK company sponsors the most, 2.

CMS Open Payments shows 1 general payment to Dr. Tefferi from 1 drug or device company in 2019. Food and beverage make up the largest share, 100% of the total. Gilead Sciences, Inc. paid the most, $106. It also lists 1 research payment totaling $92 in 2016.

Dmand AI lists 2 awards for Dr. Tefferi, most recently America's Top Doctors in 2014.

Dr. Tefferi graduated from University of Athens in 1981.

Dr. Tefferi is in network with 12 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.